Post-dilation in TAVI associated to more stroke and more paravalvular regurgitation

Courtesy of Dr. Carlos Fava.

Moderate/severe paravalvular regurgitation (PVR) after TAVR is present in 10%-14% of all cases, according to different series. The treatment of choice is post-dilation, generally effective in most cases. However, this strategy carries a risk of stroke. The true impact of this conduct is still unclear.

Endocarditis infecciosa post TAVI

 

This review analyzed 6 studies that included 5007 patients; 889 of them underwent post-dilation (17.8%). The remaining 4118 patients did not undergo post-dilation (82.2%).

 

Populations were similar, but the group undergoing post-dilation (PD) included more male patients, presented a higher rate of coronary disease, and more frequent presence of New York Heart Association functional class III/IV. No differences were observed as regards EuroSCORElog or ejection fraction.


Also read: “TAVI Without Predilation Is Feasible and Safe”


At 30 days, there were no differences in mortality (odds ratio [OR]: 1.24; 95% confidence interval [CI]: 0.88-1.74; p = 0.22) and acute myocardial infarction (OR: 0.93; 95% CI: 0.46-1.9; p = 0.85). However, the PD group tended to require definitive pacemaker implantation more frequently (OR: 1.28; 95% CI: 0.99-1.67; p = 0.06) and presented higher rates of moderate/severe PVR.

 

In 81% of all cases, PD reduced PVR by at least one grade. The rate of regurgitation remained high in patients who did not undergo PD.

 

At 1-year follow-up, there were no differences as regards mortality (OR: 0.98; 95% CI: 0.61-1.56; p = 0.92); however, among the PD group the prevalence of stroke was higher (10.2% vs. 2.6%; p = 0.0031) and PVR rates continued to be higher (OR: 3.64; 95% CI: 1.96-6.75; p < 0.001).

 

Conclusion

PD significantly improves the rate of PVR. However, careful patient selection is needed to minimize increased risk of stroke.

 

Editorial Comment

The presence of calcium at valve level is one of the greatest challenges for TAVR, and the association between higher-than-mild PVR and worse outcomes is well-known.

 

The rates of coronary or peripheral disease are associated with patients with more comorbidities and valvular calcification. This must be taken into account when deciding on the characteristics of the valve to be implanted.

 

PD has emerged as the strategy of choice for the reduction of PVR, at the cost of higher stroke rates.

 

Correct valvular assessment through an angioTAC and adequate implantation valve selection is of the utmost importance.

 

Second-generation valves have reduced the presence of PVR. The future will surely bring about much improvement in that sense.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Post-Dilation in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.

Reference: Nelson Wang, et al. Journal of Interventional Cardiology 2017;30:204-211.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...